

ESPS Peer-review Report

Name of Journal: World Journal of Clinical Urology

ESPS Manuscript NO: 10897

Title: Benefits and Risks of Erythrocyte-Stimulating Agents

Reviewer code: 00503000

Science editor: Ling-Ling Wen

Date sent for review: 2014-04-29 09:47

Date reviewed: 2014-05-20 21:45

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This is a good review about the treatment of anemia in CKD patients. Some issues need to be resolved before publication. - in Historical background, last paragraph: Myake and colleagues purified human EPO and not rHu-EPO from urine. - in 3-2. and 3.3: Authors must define "CKD5D" in 7th line, and "603 CKD 3-5 patients", "1432 CKD 3-4 patients"